Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion type Assertion NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_head.
- NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_provenance.
- NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion evidence source_evidence_literature NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_provenance.
- NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion SIO_000772 21641642 NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_provenance.
- NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion wasDerivedFrom befree-20150227 NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_provenance.
- NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion wasGeneratedBy ECO_0000203 NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_provenance.